Stocks and Investing
Stocks and Investing
Wed, January 19, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tue, January 18, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Matthew Harrison Maintained (ALVR) at Buy with Decreased Target to $45 on, Jan 18th, 2022
Matthew Harrison of Morgan Stanley, Maintained "AlloVir, Inc." (ALVR) at Buy with Decreased Target from $48 to $45 on, Jan 18th, 2022.
Matthew has made no other calls on ALVR in the last 4 months.
There is 1 other peer that has a rating on ALVR. Out of the 1 peers that are also analyzing ALVR, 0 agree with Matthew's Rating of Hold.
This is the rating of the analyst that currently disagrees with Matthew
- Mani Foroohar of "SVB Leerink" Maintained at Buy with Decreased Target to $32 on, Friday, December 17th, 2021
Contributing Sources